Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Taps Cartagenia to Provide Microarray Data Analysis Software


Cartagenia said this week that CombiMatrix, an Irvine, Calif.-based molecular diagnostics firm, has selected its Bench lab software for copy number variant analysis.

CombiMatrix will use the software to handle microarray data analysis, interpretation, and reporting for its postnatal and prenatal testing service.

Cartagenia said that it will tailor the software to CombiMatrix's variant assessment and reporting workflow so that the company can perform interpretation and reporting without having to disrupt its established operating procedures. Additionally, Cartagenia will also integrate the software with existing information technology systems at CombiMatrix.

Richard Hockett, CombiMatrix’s chief medical officer, explained that the company selected Cartagenia’s software because the company “clearly positions its solutions for clinical use," which is "in contrast to other software packages.”

Furthermore, "with our lab operations and test volumes growing, it made perfect sense to select the Cartagenia Bench platform at this time,” he said in a statement.

“We already perform hundreds of microarray analyses per month and having recently expanded testing for the prenatal marketplace, that number will grow even more,” Hockett explained. “The automation provided by Bench lab CNV gives us the ability to grow our array throughput while providing significant savings in both analysis and interpretation time and staffing.”

In addition to CombiMatrix, Cartagenia’s client list includes Credit Valley Hospital lab, an Ontario-based clinical cytogenetic laboratory (BI 5/18/2012), as well as Gene DX and the Los Angeles Children’s Hospital (BI 3/23/2012).

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.